The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC).
 
Yungan Tao
Honoraria - Merck Serono; MSD Oncology; Seagen
Consulting or Advisory Role - Merck Serono; MSD Oncology
Travel, Accommodations, Expenses - Merck Serono; MSD Oncology
 
Lillian Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca; Daiichi Sankyo/UCB Japan; Gilead Sciences; GlaxoSmithKline; Incyte; LTZ Therapeutics; Marengo Therapeutics; Medicenna; Merck; Navire; Nerviano Medical Sciences; Pangea; Pangea; Relay Therapeutics; Roche; Seagen; Tubulis GmbH; Voronoi Health Analytics
Research Funding - 23andMe (Inst); Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); LegoChem Biosciences (Inst); Loxo/Lilly (Inst); Marengo Therapeutics (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Takara Bio (Inst)
 
Lisa Licitra
Honoraria - ALTIS Omnia Pharma Service Srl; Bristol Mayers Squibb [K.K.]; Merck KGaA; Merck Serono; MSD IT
Consulting or Advisory Role - Abbvie S.r.l.; ALX Oncology; Bicara Therapeutics; Boehringer Ingelheim; EMD Ser Reaserach & Development Institute Inc.; Genmab; GlaxoSmithKline; GroupH Ltd; Janssen Research & Development; Medscape LLC; Merck Healtcare KGaA; Merck Serono; MSD; MSD; Purple Biotech; Roche; Seagan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - TAE Life Sciences
 
Barbara Burtness
Consulting or Advisory Role - ALX Oncology; Coherus Biosciences; CUE Biopharma; Genentech/Roche; GlaxoSmithKline; IO Biotech; Janssen Oncology; Merck; Merck KGaA; Merus; Mirati Therapeutics; Orphagen Pharmaceuticals; Pfizer; Rakuten Medical; Seagen; Takeda; Vaccinex
Speakers' Bureau - Clinical Education Alliance; Oncology Education
Research Funding - CUE Biopharma (Inst); Exelixis (Inst); IO Biotech (Inst); Merck; Merck (Inst)
Expert Testimony - Cel-Sci Corporation
Travel, Accommodations, Expenses - Merck; Merck
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Genmab; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; MSD; Nanobiotix; Ono Pharmaceutical; Pfizer; Rakuten Medical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nanobiotix (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical (Inst)
 
Danny Rischin
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Decibel Therapeutics (Inst); Erasca, Inc (Inst); Merck (Inst); Regeneron (Inst)
(OPTIONAL) Uncompensated Relationships - Eisai; GlaxoSmithKline; Merck; Regeneron
 
Gustavo Alves
Consulting or Advisory Role - AstraZeneca; Merck Serono; MSD Oncology
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Sanofi
Research Funding - AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BMS Brazil (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Roche (Inst); Sanofi (Inst); Zymeworks (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Iane Pinto Figueiredo Lima
Honoraria - Janssen
Travel, Accommodations, Expenses - Adium Pharma; Gilead Sciences; Roche
 
Brett Hughes
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer; Roche; Sanofi/Aventis; Takeda
Research Funding - Amgen (Inst)
 
Yoann Pointreau
No Relationships to Disclose
 
Sercan Aksoy
Honoraria - AstraZeneca; Bristol Myers Squibb; Lilly; Merck, Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer
 
Simon Laban
Honoraria - Merck Sharp & Dohme (Inst)
Consulting or Advisory Role - Boehringer Ingelheim; Bristol Myers Squibb (Inst); GlaxoSmithKline; Merck Sharp & Dohme (Inst)
Speakers' Bureau - Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - Peptides for antigen-specific immunotherapy of head and neck cancer or other cancers (EP2023/071063, patent pending)
Travel, Accommodations, Expenses - Merck
 
Richard Greil
Stock and Other Ownership Interests - Lilly (Inst); Novo Nordisk (Inst)
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Sanofi; Takeda
Research Funding - Abbvie; Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche
 
Martin Burian
No Relationships to Disclose
 
Marcin Hetnal
No Relationships to Disclose
 
Jean-Pierre Delord
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); MSD Oncology (Inst); Transgene (Inst)
 
Laurent Kassalow
Employment - Merck
Consulting or Advisory Role - Merck
 
Behzad Bidadi
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
Travel, Accommodations, Expenses - Merck
 
Burak Gumuscu
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Jean-Pascal Machiels
Consulting or Advisory Role - ALX Oncology; ANAVEON (Inst); Astellas Pharma (Inst); AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CUE Biopharma; CureVac (Inst); eTHERNA; F-star; Genmab (Inst); GlaxoSmithKline (Inst); Incyte; Innate Pharma; IPSEN (Inst); ITeos Therapeutics; Janssen; Merck Serono; Merus (Inst); MSD Oncology (Inst); NEKTAR; Novartis; Pfizer; Roche; Seagen (Inst); Seagen (Inst)
Research Funding - Bayer; Janssen; Novartis; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Gilead Sciences; Merck Serono (Inst); MSD; Pfizer
Other Relationship - PsiOxus Therapeutics